Market Research Report

A quick peek into the report

Next-Generation Breast Cancer Diagnostic and Screening Market - A Global Market and Regional Analysis

Focus on Technology, Cancer Sub-Type, Biomarker, Offering, End User, and Country Analysis - Analysis and Forecast, 2023-2032

 
Some Faq's

Frequently Asked Questions

The next-generation breast cancer diagnosis and screening includes several genomic and molecular-based assays developed using different technologies, including immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), next-generation sequencing (NGS), and real-time polymerase chain reaction (RT-PCR), among others. The diagnostics assay uses the potential breast-tumor markers and facilitates the yielding of exceptionally fast results for early clinical decision-making.

The key trends going on in the market are the adoption of liquid biopsy for breast cancer diagnosis and the complete automation of next-generation techniques.

The global next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, alliances, product launches, regulatory and legal activities, funds, grants, and mergers and acquisitions. According to BIS Research analysis, partnerships, alliances, and business expansions accounted for the maximum number of key developments, followed by regulatory and legal activities and mergers and acquisitions.

A new entrant can focus on multiple biomarker assessment tests, liquid biopsy tests, and incorporation of artificial intelligence (AI) at molecular levels.

The following can be considered as some of the USPs of this report:

· Overview of the overall oncology molecular diagnostics market

· Key trends and opportunities of the market

· Regulatory framework and list of regulatory-approved products

· Breast cancer clinical trials

· Advantages and limitations of different techniques

· Product pricing

· Impact of COVID-19 on the market

· Market dynamics, including drivers and restraints

· Opportunity mapping by each segment and by companies

· Region and country-level analysis, including market dynamics and market size and forecast

· Market share analysis of key players in the market

The companies developing next-generation genomic and molecular-based assays for breast cancer diagnosis and screening or looking to leverage such assays in the field of oncology (breast cancer) should buy this report. Academic and research institutes working on the development of such assays/techniques for breast cancer can also buy this report.

Similar Product

You may also like

Middle East Molecular Diagnostics Market - Country Analysis
Published Year: 2022

Middle East Molecular Diagnostics Market - Country Analysis: Focus on Product, Testing Location, Tec

The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031...

Molecular Diagnostics Market - A Global and Regional Analysis
Published Year: 2021

Molecular Diagnostics Market - A Global and Regional Analysis: Focus on Product, Testing Location, A

The global molecular diagnostics market is projected to reach $24,228.0 million by 2031 from...

Global Rare Disease Diagnostics Market
Published Year: 2021

Global Rare Disease Diagnostics Market: Focus on Disease, Trait Type, Products, Age Group, Test Type

The global rare disease diagnostics market has been currently witnessing a rapid growth and is...